基因治疗后的肝脏表现
Akash Roy1, Shalini Bansal2, Anand Kulkarni3
1Department of Gastroenterology, Institute of Gastrosciences and Liver Transplantation, Apollo Multispeciality Hospitals, Kolkata, India.
基因疗法可能会导致肝损伤,主要是由于对病毒载体的免疫反应. 监测和免疫抑制,通常是用皮质类固醇,是控制这种潜在肝毒性的关键.
科学领域:
- 生物医学科学 生物医学科学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 基因疗法利用遗传物质,通常通过病毒载体,治疗疾病.
- 人们对基因疗法的兴趣日益增加,同时也担心潜在的肝毒性.
- 肝毒性机制包括病毒载体集成和免疫反应,免疫激活是主要的.
研究的目的:
- 审查基因疗法诱导的肝毒性机制和管理.
- 强调治疗前查和持续监测肝脏健康的重要性.
- 讨论当前和潜在的治疗策略来管理肝损伤.
主要方法:
- 对基因治疗,肝毒性机制和临床管理策略的文献综述.
- 基因治疗后报告的肝损伤病例的分析.
- 综合有关诊断方法,监测协议和治疗方式的数据.
主要成果:
- 肝毒性呈现变化,从提升的氨基转移酶 (20-80%) 到罕见的急性肝衰竭.
- 发生是不可预测的,受患者因素,载体类型/剂量和免疫反应的影响.
- 皮质类固醇是第一线免疫抑制剂;二线药物用于耐火病例.
结论:
- 治疗前对肝病的查和非侵入性测试是必不可少的.
- 涉及肝病学家的多学科合作对于优化肝脏健康至关重要.
- 缺乏管理肝毒性的标准化预防和反应策略,需要进一步研究.
更多相关视频
09:13Study of Viral Vectors in a Three-dimensional Liver Model Repopulated with the Human Hepatocellular Carcinoma Cell Line HepG2
Published on: October 24, 2016
09:35Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
Published on: February 2, 2018
相关概念视频
Gene Therapy
Hepatic Drug Excretion: Influencing Factors
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
Hepatic Drug Clearance: Role of Transporters
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
